Discover how resources from the Medical Device Innovation Consortium (MDIC) can help advance clinical trials for better patient outcomes.
In the post-op SAKK 09/10 trial, only patients in the higher PORTOS score group benefited from radiation therapy dose escalation (clinical progression free survival HR 0.19, 95% CI 0.05-0.70; p = 0.01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback